We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Oxford Biomedica Announces Board Appointment

Oxford Biomedica Announces Board Appointment

Oxford Biomedica Announces Board Appointment

Oxford Biomedica Announces Board Appointment

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Biomedica Announces Board Appointment"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford BioMedica has announced that, with immediate effect, Dr Mike McDonald has been promoted to the Board as an executive director.

He will maintain his title of Chief Medical Officer. His primary responsibilities include the Company’s clinical development activities and regulatory affairs.

Mike has over 20 years of experience in clinical drug development and regulatory leadership. He joined Oxford BioMedica in September 2005 from Seattle Genetics, a US-based biotechnology company, where he was Chief Medical Officer. 

Mike spent nine years with Eli Lilly serving as Worldwide Vice President, Clinical Research and Medical Affairs, and was previously at SmithKline Beecham for seven years where he was involved in worldwide clinical development, regulatory management and was a member of the pharmaceutical development strategy committee.

From these positions Dr McDonald contributed to the registration and commercialisation of many important pharmaceuticals.

He received his medical degree from Edinburgh University, he is a member of the Royal College of Physicians in London, holds a Diploma in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Physicians.

Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of Oxford BioMedica, said, "Mike has already made a significant and valuable contribution to the Company since joining last year and has been instrumental in the preparations for our planned Phase III trial of TroVax in renal cell carcinoma. We are delighted to welcome him to the Board."